Secondary central nervous system involvement is an uncommon event that typically occurs early in the natural history of diffuse large B-cell lymphoma and presents as leptomeningeal dissemination in two-thirds of cases. The prognosis of this event is dismal, and treatment options are meagre. Although major validated risk factors for central nervous system dissemination are clinical, concomitant MYC/BCL2 rearrangements as well as MYC/BCL2 protein expression have been recently associated with an increased risk of this complication. Here we present the first case, to our knowledge, of a MYC/BCL6-positive double-hit diffuse large B-cell lymphoma relapsing in the leptomeninges that achieved an outstanding durable remission with single-agent lenalidomide following salvage chemotherapy.

Durable remission in a patient with leptomeningeal relapse of a MYC/BCL6-positive double-hit DLBCL treated with lenalidomide monotherapy / Salati, Massimiliano; Tarantino, Vittoria; Maiorana, Antonino; Bettelli, Stefania Raffaella; Luminari, Stefano. - In: HEMATOLOGICAL ONCOLOGY. - ISSN 0278-0232. - (2017), pp. 1-3. [10.1002/hon.2315]

Durable remission in a patient with leptomeningeal relapse of a MYC/BCL6-positive double-hit DLBCL treated with lenalidomide monotherapy

Salati, Massimiliano;Tarantino, Vittoria;MAIORANA, Antonino;BETTELLI, Stefania Raffaella;LUMINARI, Stefano
2017

Abstract

Secondary central nervous system involvement is an uncommon event that typically occurs early in the natural history of diffuse large B-cell lymphoma and presents as leptomeningeal dissemination in two-thirds of cases. The prognosis of this event is dismal, and treatment options are meagre. Although major validated risk factors for central nervous system dissemination are clinical, concomitant MYC/BCL2 rearrangements as well as MYC/BCL2 protein expression have been recently associated with an increased risk of this complication. Here we present the first case, to our knowledge, of a MYC/BCL6-positive double-hit diffuse large B-cell lymphoma relapsing in the leptomeninges that achieved an outstanding durable remission with single-agent lenalidomide following salvage chemotherapy.
15-giu-2016
1
3
Durable remission in a patient with leptomeningeal relapse of a MYC/BCL6-positive double-hit DLBCL treated with lenalidomide monotherapy / Salati, Massimiliano; Tarantino, Vittoria; Maiorana, Antonino; Bettelli, Stefania Raffaella; Luminari, Stefano. - In: HEMATOLOGICAL ONCOLOGY. - ISSN 0278-0232. - (2017), pp. 1-3. [10.1002/hon.2315]
Salati, Massimiliano; Tarantino, Vittoria; Maiorana, Antonino; Bettelli, Stefania Raffaella; Luminari, Stefano
File in questo prodotto:
File Dimensione Formato  
Salati_et_al-2016-Hematological_Oncology.pdf

non disponibili

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 101.3 kB
Formato Adobe PDF
101.3 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
double hit lenalidomide monotherapy-Hematol Oncol-Revised Version.pdf

accesso aperto

Tipologia: Pre-print dell'autore (bozza pre referaggio)
Dimensione 148.29 kB
Formato Adobe PDF
148.29 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1111940
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 2
social impact